electroCore (ECOR) Planet MicroCap Las Vegas 2026 summary

Business overview and strategy

• Focused on bioelectronic health and wellness with FDA-cleared prescription and direct-to-consumer products.

• Revenue growth driven by targeting reliably reimbursed markets, especially the VA, achieving 50% CAGR over five years.

• Commercialization strategy leverages a variable sales model and experienced leadership to expand in federal and commercial markets.

• Two main product classes: prescription-based (mainly for VA) and general wellness (direct-to-consumer and B2B for military use).

• Platform technology approach with potential for multiple indications and integration with consumer tech.

Product performance and market expansion

• gammaCore, the flagship product, is a non-opioid pain therapeutic for severe headaches, primarily sold to the VA.

• Margins expand as patients transition to longer-duration prescriptions, with higher ASP for multi-year products.

• Acquired NeuroMetrix in May 2025, rapidly scaling its fibromyalgia device revenue from $50,000/month to $400,000/month within a year.

• Truvaga, a general wellness product, doubled revenue from $2.5M in 2024 to $5M in 2025, with a new focus on profitable growth at 30%-50% annually.

• TAC-STIM, developed with the Air Force, supports cognitive performance in military settings but has lumpy revenue due to government procurement cycles.

Market opportunities and future plans

• Large addressable markets: VA (9.5M lives), Kaiser Permanente (12.5M lives), and broader health and wellness sector.

• Only 2.5% penetration in the VA headache population and one-third of facilities adopting the fibromyalgia product, indicating significant upside.

• Kaiser Permanente formulary win in 2025 seen as a catalyst for broader commercial insurer adoption.

• Ongoing clinical trials for new indications (PTSD, long COVID, stroke, neuropathy) to expand platform use.

• Plans to reduce sales and marketing expenses as a percentage of revenue and achieve cash flow breakeven and adjusted EBITDA positive.